Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023890 (cirrhosis)
 42,195 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In order to understand the situation of HGV infection in various populations in Liuzhou prefecture of Guangxi, Zhuangzu Autonomous Region, and also to compare the HGV, HBV, HCV infections between intravenous drug abusers and healthy persons (those for physical examination, the same below), the anti-HGV, -HCV and HBVM (HBsAg, HBsAb, HBeAg, HBeAb, HBcAb) were detected by ELA and, besides, tested further the 20 anti-HGV seropositive cases for HGV-RNA by RT-nPCR. The results showed that in the populations tested, the HGV seropositive rate was 9.8% (106/1079), separately they were 23.8% (5/21), 21.1% (23/109), 12.5% (6/48), 12.0% (6/50), 12.0% (20/166), 9.3% (3/32), 8.2% (34/413), 4.3% (6/140), and 3.0% (3/100) in liver cirrhosis, intravenous drug abusers, repeated blood and blood products transfused patients, hepatocellularcarcinoma patients, viral hepatitis, haemodialysis patients, healthy persons, paid blood donors and healthy pregnant women respectively. In intravenous drug abusers, the HGV, HBV, HCV infection rate were 21.2% (23/109), 75.3% (82/109) and 7.3% (8/109) respectively, while they were 8.2% (9/109), 20.1% (22/109), and 1.8% (2/109) in healthy persons respectively. These data showed that Liuzhou prefecture of Guangxi was HGV high epidemic area, HGV infection rate was higher in populations of intravenous drug abusers, viral hepatitis, liver cirrhosis and repeatedly blood and blood products transfused patients, even in pregnant women the HGV infection also occurred. There was a significant difference of HGV, HBV, HCV infection rates between intravenous drug abusers and healthy persons (P < 0.005).
 ...
PMID:[Investigation of HGV infection in various populations in Guangxi]. 1252 48

Background. Emerging evidence suggests that nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery diseases and arrhythmias. The FibroScan (Echosens, France), a widely available, noninvasive device, is able to detect liver fibrosis and steatosis within this patient population. However, the FibroScan is currently contraindicated in patients with cardiac pacemakers (PM) or implantable cardioverter-defibrillators (ICD). Objective. To determine the safety profile of FibroScan testing in patients with PM or ICD. Methods. Consecutive outpatients undergoing routine device interrogations at a tertiary level teaching hospital underwent simultaneous liver stiffness measurements. PM or ICD performance data, device types, patient demographics, medical history, and previous laboratory and conventional liver imaging results were collected. Results. Analysis of 107 subjects with 33 different types of implanted cardiac devices, from 5 different companies (Medtronic, Sorin, ELA Medical, Boston Scientific, and St. Jude), did not demonstrate any adverse events as defined by abnormal device sensing/pacing or ICD firing. This population included high risk subjects undergoing active pacing (n = 53) and with right pectoral PM placement (n = 1). None of the subjects had any clinical signs of decompensated congestive heart failure or cirrhosis during the exam. Conclusion. TE with FibroScan can be safely performed in patients with PM or ICD.
 ...
PMID:Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators. 2834 45